DNMT1 and cervical carcinoma: Moreover, the FDA-approved drug, olsalazine, a nucleoside DNMT inhibitor was first approved for the treatment of inflammatory bowel disease and ulcerative colitis, and later (2014) was shown to inhibit DNMT activity in cervical cancer cell lines [35].